Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

Document › Details

BiondVax Pharmaceuticals Ltd.. (1/28/21). "Press Release: BiondVax Announces Third Quarter 2020 Financial Results & Business Update". Jerusalem.

	Organisation	BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)
	Organisation 2	European Investment Bank (EIB)
	Group	EU (govt)
	Product	M-001 universal flu vaccine (BiondVax)
	Product 2	anti-infective drug
	Person	Reichman, Amir (BiondVax 202103– CEO before GSK Vaccines + Novartis Vaccines + NeuroDerm)
	Person 2	Phillipson, Joshua E. (BiondVax 201707 Business Development Manager)

Original document
accessed by [iito] on 2021-01-30

Record changed: 2021-02-04

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)

[1] BiondVax Pharmaceuticals Ltd.. (1/29/21). "Press Release: BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares". Jerusalem....
[2] BiondVax Pharmaceuticals Ltd.. (1/28/21). "Press Release: BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares". Jerusalem....
[3] BiondVax Pharmaceuticals Ltd.. (1/21/21). "Press Release: BiondVax Announces Appointment of Amir Reichman as New CEO". Jerusalem....
[4] BiondVax Pharmaceuticals Ltd.. (10/23/20). "Press Release: BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate". Jerusalem....
[5] BiondVax Pharmaceuticals Ltd.. (4/30/18). "Press Release: BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update". Ness Ziona....
[6] BiondVax Pharmaceuticals Ltd.. (4/11/18). "Press Release: BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of its Universal Flu Vaccine in the United States". Ness Ziona....
[7] BiondVax Pharmaceuticals Ltd.. (12/5/17). "Press Release: BiondVax’s CEO Issues Letter to Shareholders". Ness Ziona....
[8] BiondVax Pharmaceuticals Ltd.. (9/18/17). "Press Release: BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-Allotment Option". Ness Ziona....
[9] BiondVax Pharmaceuticals Ltd.. (9/14/17). "Press Release: BiondVax Announces Pricing of Public Offering of American Depositary Shares". Ness Ziona....
[10] BiondVax Pharmaceuticals Ltd.. (9/13/17). "Press Release: BiondVax Announces Public Offering of American Depositary Shares". Ness Ziona....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top